Gangaputra SS, et al. - In this retrospective analysis of cohort study data, researchers compared mycophenolate mofetil (MMF) to methotrexate (MTX) as corticosteroid-sparing therapy for ocular inflammatory diseases. From the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, candidates have been identified. The study sample consisted of 352 subjects who were taking single agent immunosuppression with MTX or MMF at four tertiary uveitis clinics. Data reported that the time-to-success was shorter (more favorable) for MMF than MTX. The proportion achieving success was higher at every point in time for MMF than MTX from 2-8m then converges at 9 months adjusting for covariates. The findings indicate that in achieving corticosteroid-sparing success in ocular inflammatory diseases, MMF can be faster than MTX on average.